Form 4: Janux Therapeutics Director Receives Equity Grant

Director Vickie L. Capps was granted 5,500 restricted stock units and 15,500 stock options by Janux Therapeutics, Inc.

Summary

• Director Vickie L. Capps acquired 5,500 restricted stock units (RSUs) on June 11, 2026.
• The director also received a grant of 15,500 stock options with an exercise price of $13.66 per share.
• Following these transactions, the director's total beneficial ownership of common stock stands at 79,598 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard retention and incentive structure for board members.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and exercise of these equity grants.

Risks

• Market price volatility affecting the value of the granted options.
• Dependence on continued service for the vesting of both RSUs and stock options.

Future Outlook

The equity grants are subject to vesting conditions tied to the director's continuous service and the date of the next annual stockholders' meeting.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value creation.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for NASDAQ-listed biotechnology companies.
• Vesting schedules tied to annual meetings are common for non-employee directors in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of RSUs on June 11, 2027, or the next annual meeting.
• Vesting of stock options in equal monthly installments over 12 months.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Insider Trading, Equity Compensation, Director Compensation